WuXi XDC Cayman Inc. (2268.HK)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Jincai Li Ph.D.
|
CEO & Executive Director | 5.42M | -- | 1973 |
|
Mr. Xiaojie Xi
|
CFO & Executive Director | 5.02M | -- | 1976 |
|
Mr. Jingwei Zhang
|
COO & Executive Director | 2.73M | -- | 1969 |
|
Dr. Meiying Zhu
|
Chief Technology Officer | -- | -- | 1966 |
|
Ms. Yuan Fang
|
Joint Company Secretary, Head of IR, Capital Markets, Corporate Communication and Public Affairs | -- | -- | -- |
|
Ms. Man Nar Chung
|
Joint Company Secretary | -- | -- | -- |
|
Dr. Jianjun Luo
|
Vice President | -- | -- | 1968 |
WuXi XDC Cayman Inc.
- Sector:
- Healthcare
- Industry: Diagnostics & Research
- Full Time Employees:
- 3,628
Description
WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.
Corporate Governance
Upcoming Events
August 24, 2026 at 8:10 AM UTC
WuXi XDC Cayman Inc. Earnings Date
Recent Events
Recent Events Information Not Available
